Tag Archives: V

Boeing Will Close 2017 as Top DJIA Stock

Boeing Co.’s (NYSE: BA) share price added less than half a point last week but it was not for lack of good news. With just a week to go in 2017, the aerospace giant is a sure thing to close out the year as the best performing stock among the 30 stocks that make up the Dow Jones Industrial Average (DJIA). Shares gained $1.76 last week to boost the year-to-date gain to nearly 90%.

Of the three other Dow stocks closest to Boeing’s yearly gain, Caterpillar Inc. (NYSE: CAT) rose by about 6.2% to a gain of nearly 68% for the year, Apple Inc. (NASDAQ: AAPL) added about 0.6% to close the week up just over 51% for the year to date, and Visa Inc. (NYSE: V) dropped about 1% to lower its annual gain to just over 44%.

Boeing’s week began with a final determination from the U.S. Department of Commerce on Boeing’s complaint against Canadian aircraft maker Bombardier for dumping the company’s CS-100 at below cost in the United States. The agency reiterated its 300% duty on imported Bombardier planes seating 100 to 150 passengers.

The U.S. International Trade Commission (ITC) will now rule on whether Boeing was harmed by Bombardier’s sale. If not, the complaint and the tariff disappear unless Boeing appeals. If the ITC does conclude that the sale harmed Boeing, Bombardier’s CS-100 planes imported into the United States will be charged the duty fees. Bombardier will certainly appeal.

On Thursday Boeing signed a firm order with UAE-based flydubai airlines for 175 of the company’s 737 MAX jets. The airline committed to the order at the Dubai Air Show last month, but the firm order adds the planes to Boeing’s backlog.

Boeing also confirmed on Thursday that it has discussed a “possible combination” with Brazil’s Embraer S.A. (NYSE: ERJ), a response to the deal Bombardier struck with Airbus in which the European company took control of Bombardier’s C Series program. A deal between Boeing and Embraer is no sure thing, mainly because the Brazilian government holds a controlling interest in Embraer.

On Friday, Boeing announced that it has sold a KC-46 refueling tanker to Japan on fixed-price contract valued at $279 million. This could be a big deal because it is the first KC-46 Boeing has sold to a non-U.S. buyer.

The U.S. Air Force also awarded Boeing a contract to sell 36 F-15 fighter jets to Qatar in a deal worth $6.1 billion. The sale had originally been set at 72 aircraft with a contract value of more than $21 billion.

Boeing stock closed at $295.10 on Friday, up less than 0.1% on the day, in a 52-week trading range of $154.96 to $97.37. The high was posted Friday morning. The 12-month consensus price target is $299.33, down about $7.80 from last week’s target. The low price target is $203 and the high is $350.

24/7 Wall St.
General Electric Will Certainly Be 2017’s Worst DJIA Stock

Dividend Hike Helps Boeing Retain Position as Top DJIA Stock

Boeing Co.’s (NYSE: BA) share price added about 2.8% last week to maintain its position as the best performing among the 30 stocks that make up the Dow Jones Industrial Average (DJIA). Shares gained $8.04 last week to boost the year-to-date gain to nearly 89%.

Of the three other stocks closest to Boeing’s yearly gain, Caterpillar Inc. (NYSE: CAT) rose by about 1.9% to a gain of over 58% for the year, Apple Inc. (NASDAQ: AAPL) added about 2.7% to close the week up just over 50% for the year to date and Visa Inc. (NYSE: V) tacked on 1.8% to bring its annual gain to nearly 46%.

Last week was a busy one for Boeing, at least for its public affairs staff. The company raised its dividend, approved a new share buyback program, lost a military jet order to Canada, lost a multibillion passenger jet order to arch-rival Airbus and then read the news about the shake-up at the top of its European competitor.

As expected, Boeing lifted its dividend following Monday’s board of directors meeting. The 20% increase, from $5.68 to $6.84 annually per share, was accompanied by a new share repurchase plan valued at $18 billion. The company posted a new 52-week high on Tuesday.

In a request for bids on an order for 88 new military fighter jets, the government of Canada included language aimed squarely at Boeing in retaliation for the company’s complaint against Bombardier’s sale of 75 CS-100 passenger jets to Delta.

Thursday got off to a rocky start with the announcement from Delta Air Lines that it had placed an order for 100 Airbus A321neo single-aisle passenger jets, along with options on another 100. At list prices the deal is worth around $12.7 billion. Boeing competed hard for this one and the loss, though not welcome, is reasonably insignificant. The company’s backlog of single-aisle (737 family) jets totals more than 4,000.

The week ended with the announcement that Airbus CEO Tom Enders will not seek to extend his contract when it ends in April 2019 and COO Fabrice Br茅gier announced he will leave the company this coming February. These are just two of manytop executives who are retiring or leaving soon.

Boeing stock closed at $293.34 on Friday, up less than 0.1% on the day, in a 52-week trading range of $154.96 to $97.37. The high was posted Friday morning. The 12-month consensus price target is $290.43, up about $5 from last week’s target. The low price target is $203 and the high is $350.

24/7 Wall St.
General Electric Holds On as 2017’s Worst DJIA Stock

5 ‘Strong Buy’ Dividend Growth Stocks for 2018

What is the holy grail of dividend investing? Stocks in strong companies that pay out a high dividend yield. The yield can provide a steady source of income every quarter, which will hopefully increase over time. You can even reinvest the dividend back into the company to further bump up your holding. Plus, dividend growth stocks from financially healthy companies can also help you to hedge your risk against more volatile stocks.

So how we can pinpoint these elusive stocks? In this case, I used TipRanks’ innovative stock screener. The screener is a great way to find stocks that match your investing criteria and have significant support from the Street’s best analysts. Here I set the filter for stocks with a “positive,” “high” or “very high” dividend yield and a “strong buy” top analyst consensus rating.

These are the Street’s top analysts according to their success rate and average return. I left the other filters open e.g. sector, market cap, etc. From the list pulled up by the screener, I specifically searched for stocks with big dividend growth and strong potential rather than just the current yield rate.

A stock that pays a high dividend yield is ultimately disappointing in the long-run if the dividend shrinks rather than grows. And a bullish company with an impressive dividend growth rate is a great sign that the dividend will continue to go one way: up.

Bearing that in mind, let’s dive in and take a closer look at these top five stock picks:

Top Dividend Growth Stocks: Starbucks investorplace.com/wp-content/uploads/2016/09/sbuxmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/09/sbuxmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Adrianna Calvo via Stock Snap

The creator of the Unicorn Frappuccino, Starbucks Corporation (NASDAQ:SBUX) pays its investors a relatively high dividend yield of 2.11%. At the moment, SBUX is trading ex-dividend until the payout date on Dec. 1, 2017.

This means only investors who have already purchased SBUX shares will receive this 30-cent dividend payout — up 5 cents from the previous payment. Indeed, over the past 10 years, Starbucks displays an encouraging 10-year dividend growth rate of 500%.

Luckily for investors, the stock’s “strong buy” rating suggests that dividends will keep growing. Analysts are optimistic about the growth And now could be a smart time to invest, with shares at $56.8, some ways off the $64.60 seen in June.

Management has just officially reduced guidance with a new long-term EPS growth target of 12%-plus. According to Oppenheimer’s Brian Bittner this was the right move. He says the reduction was widely expected, and the new target sets a more appropriate bar for management.

Wells Fargo’s Bonnie Herzog agrees and recommends buying dips. She says the company’s $15B three-year share repurchase program “signals to the market its commitment to deliver above-industry shareholder returns irrespective of operating headwinds.”

Meanwhile, her $63 price target comes out slightly above the $62.19 average analyst price target. In the past three months, 13 out of 16 analysts have recorded a bullish sentiment on SBUX.

Top Dividend Growth Stock: Lam Research investorplace.com/wp-content/uploads/2017/11/lrcxmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/11/lrcxmsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/11/lrcxmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: shutterstock

This top semiconductor stock is one of the best tech stocks out there. In the past year, the stock has more than doubled from just $106 to the current share price of $216. And now Lam Research Corporation (NASDAQ:LRCX) has just announced two fresh capital return actions.

First, a $2.0B 12-18 month share repurchase program has emerged. Secondly, the dividend was hiked 11.0% from $0.45 to $0.50. That’s the second boost since 2014’s initiation with a payout ratio at ~23% of C18E US free cash flow.

Top B.Riley FBR analyst Craig Ellis applauds these two new initiatives. He says they “lend further support to our bullish excess growth thesis.” And ultimately Ellis concludes “we are encouraged by management’s latest shareholder value creation moves and look for upbeat 4Q Semi trends over the next few months to lend further confidence in C18’s Semi Cap fundamentals.”

He reiterated his “buy” rating with a $250 price target on Nov. 14. Considering that the stock is trading at just $216 this suggests sweet upside potential of 15.3% from the current share price.

Note that this five-star analyst seems to know what he is talking about- he is ranked number 1 on TipRanks (out of 4,731 tracked analysts). On LRCX specifically, Ellis boasts a strong track record with 100% success rate and 61.7% average return across his 12 stock ratings.

Overall, Lam Research has a very confident “strong buy” outlook from the Street with 10 “buy” ratings and just 1 hold rating in the past three months.

Top Dividend Growth Stock: UnitedHealth Group UnitedHealth (UNH)investorplace.com/wp-content/uploads/2017/07/unhmsn2-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/07/unhmsn2-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/07/unhmsn2-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

This giant health care insurer boasts a very impressive dividend growth rate. UnitedHealth Group Incorporated (NYSE:UNH) has increased its dividend for seven of the last ten years. Back in 2012, the company paid a dividend of $0.2125. Now that number stands at $0.75. We can also look at it from an annual perspective. In 2012 the company paid a total dividend of $0.80. Fast forward to 2017 and the company looks set to pay a dividend of just over $2.87.

The icing on the cake: this stock has received 10 consecutive “buy” ratings from analysts over the last three months. These analysts have an average price target on the stock of $225- 6% upside from the current share price. Note however that the price targets are moving increasingly higher- an encouraging sign of the company’s direction going forward.

Top Cantor Fitzgerald analyst Steven Halper recently wrote an interesting report on UNH. He draws attention to UNH’s fast-growing health services business Optum- which already generated huge revenue in 2016 of $84 billion.

“Optum’s capabilities enhance the operating performance of UHC and represent an important growth vehicle for UNH. UNH has been aggressively deploying capital to build Optum in recent years. Given the combination of strong UHC fundamentals and strong growth at Optum, we believe UNH shares should be a core holding for large-cap portfolio managers” says Halper.

He has a “buy” rating and $225 price target on the stock. It’s also worth mentioning that Halper’s track record that speaks for itself. This five-star analyst boasts a 100% success rate and 26.4% average return across his 23 ratings on UNH stock.

Top Dividend Growth Stock: General Dynamics General Dynamics GD stockinvestorplace.com/wp-content/uploads/2016/06/gdmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/06/gdmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/06/gdmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/06/gdmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/06/gdmsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/06/gdmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/06/gdmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/06/gdmsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/06/gdmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Alan Wilson via Flickr (Modified)

This American multinational corporation is one of the world’s largest aerospace and defense contractors based on revenue. From a dividend perspective, General Dynamics Corp (NYSE:GD) offers a yield of 1.68% and a payout of $0.84. This works out at an annualized dividend payment of $3.36. The company has recorded dividend growth for a whopping 25 consecutive years- giving it the nickname “dividend aristocrat.”

Shares in GD are trading slightly lower following mixed Q3 results at the end of October. Indeed, prices are now at $200 from close to $214 last month. For the savvy investor, however, this could represent a buying opportunity. Top Cowen & Co analyst Cai Rumohr has not lost faith in GD.

On the contrary, he says the stock’s “long-term thesis (defense growth; Gulfstream upturn; lots of firepower) remains intact.” And bear in mind that over the past five years this stock has grown fairly consistently from $66 to $200.

Interestingly Rumohr also notes that: “GD trades for a 17% discount to defense big caps LMT, NOC, & RTN on C18 EV/EBITDA, despite peer-high 6-7% revenue growth in 2018-2019 driven by comparable domestic & foreign defense programs.”

His bullish outlook is echoed by the majority of the Street. General Dynamic’s “strong buy” consensus breaks down into five “buy” ratings versus just one “hold” rating in the previous three months.

With an average price target of $226.67, analysts are predicting considerable upside of over 13% from the current share price.

Top Dividend Growth Stock: Visa v stockinvestorplace.com/wp-content/uploads/2017/07/vmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/07/vmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/07/vmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/07/vmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/07/vmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/07/vmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/07/vmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/07/vmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/07/vmsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2017/07/vmsn-170×93.jpg 170w” sizes=”(max-width:728px) 100vw, 728px” />Source: Shutterstock

Last but by no means least, we have leading global payments company Visa Inc (NYSE:V). For an investor, Visa is something of a dividend growth dream. The stock boasts a current yield of 0.7%- and a 10-year dividend growth rate of 625%. This breaks down into a very impressive 8 consecutive years of growth. Add to the mix a very low payout ratio and strong earnings potential and you can see why this is a top stock to track right now.

Cantor Fitzgerald’s Joseph Foresi is one of the top 50 analysts on TipRanks. He only recently began to cover V stock, but is already displaying a very bullish sentiment. “We remain attracted to Visa’s dominant position in the global card network market and its strong, recognizable international brand” wrote Foresi on Oct. 26.

Following strong results for the fiscal fourth quarter, Foresi sees promise from “Visa’s opportunity to capitalize on the global conversion of cash into credit, international opportunities, and digital payment tailwinds.”

In total, this “strong buy” stock boasts 16 “buy” ratings in the past three months versus just two “hold” ratings. These analysts have an average price target on the stock of $123.06- with $135 on the high-end. Considering that Visa is now trading at $111.97, this translates into upside potential of 10% from the current share price.

Which stocks are the top 25 analysts recommending right now? Find out here.

TipRanks offers investors the latest insight into eight different sectors by tracking the activity of 4,500 analysts, 5,000 financial bloggers and even 37,000 corporate insiders. As of this writing, Harriet Lefton did not hold a position in any of the aforemen

Boeing Retains Perch as Best DJIA Stock This Year

Boeing Co.’s (NYSE: BA) share price added about 0.8% last week and easily held onto its position as the best performing stock among the 30 stocks that make up the Dow Jones Industrial Average. Shares gained $3.62 last week to boost the year-to-date gain to nearly 71%.

Of the three other stocks closest to Boeing’s yearly gain, Apple Inc. (NASDAQ: AAPL) added more than 2% to close the week up 51% for the year to date; Caterpillar Inc. (NYSE: CAT) rose by about 0.8% to a gain of more than 48%; and Visa Inc. (NYSE: V) tacked on 0.9% to bring its annual gain to 43.5%.

The week got off to a good start with Sunday’s announcement that Boeing had finalized an order from aircraft lessor Avolon for 55 of the company’s 737 MAX 8s (737-8) and 20 737 MAX 10s (737-10). The original memorandum of understanding (MOU) was announced in June at the Paris Air Show and Sunday’s deal includes an option for an additional 20 737-8s.

At Boeing’s list prices for the new aircraft, the order with options is valued at nearly $11 billion. Boeing added the 75 planes to its order book on Tuesday, lifting net orders for all versions of the 737 for the year to date to 505.

Analysts continue to be upbeat about the company’s performance. Barron’s cited Jefferies analyst Sheila Kahyaoglu’s forecast for free cash flow rising from an expected $10.5 billion this year to $12 billion by 2020. Kahyaoglu also raised her price target from $300 to $312.

Carter Copeland at Melius Research also cited Boeing’s massive free cash flow, but pins its outlook for the company on the introduction of the “new mid-size aircraft,” also known as the NMA or the 797. Copeland noted that the company’s order tally spikes about half when Boeing launches a new product and he believes that the a launch for the 797 is closer than the market thinks.

Boeing stock closed at $265.88 on Friday, up about 0.3% on the day, in a 52-week range of $148.32 to $267.62. The 12-month consensus price target is $281.04, 21 cents higher than last week’s target. The low price target is $170 and the high is $350.

24/7 Wall St.
The End Is Near for the Airbus A380

Top 10 Medical Stocks To Invest In 2018

Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.

Getty Images

Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.

Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:

Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.

Top 10 Medical Stocks To Invest In 2018: Olympic Steel Inc.(ZEUS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Olympic Steel, Inc. (NASDAQ: ZEUS) got a boost, shooting up 17 percent to $22.55. Olympic Steel reported a Q1 net income of $7.7 million, after posting a loss in the year-ago period.

  • [By Lisa Levin]

    Wednesday afternoon, the basic materials shares climbed by 1.09 percent. Meanwhile, top gainers in the sector included Olympic Steel, Inc. (NASDAQ: ZEUS), up 7 percent, and Aluminum Corp. of China Limited (ADR) (NYSE: ACH), up 7 percent.

  • [By Lisa Levin]

    Basic materials sector was the top gainer in the US market on Monday. Top gainers in the sector included Haynes International, Inc. (NASDAQ: HAYN), Cliffs Natural Resources Inc (NYSE: CLF), and Olympic Steel, Inc. (NASDAQ: ZEUS).

Top 10 Medical Stocks To Invest In 2018: Iridium Communications Inc(IRDM)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap satellite stock Iridium Communications (NASDAQ: IRDM) reportedQ2 2017 earnings before the market opened on Thursday with results beating expectations. Total revenueincreased 2% to $111.6 million which consisted of $86.6 million of service revenue and $25.0 million of revenue related to equipment sales and engineering and support projects.Service revenue, which represents primarily recurring revenue from Iridium’s growing subscriber base, grew 4% and was 78% of total revenue. The Company ended the quarter with 913,000 total billable subscribers, which compares to 823,000 for the year-ago period and is up from 869,000 for the quarter ended March 31, 2017.Total billable subscribers grew 11% year-over-year, driven by growth in M2M and government customers. Net income was $24.8 million versus $26.9 million for the second quarter of 2016. The CEO commented:

  • [By Jim Robertson]

    Trump’s proposal to spin off air traffic control from the Federal Aviation Administration (FAA) bodes well for small cap satellite stock Iridium Communications (NASDAQ: IRDM), but theres a bigger opportunity for the Company in theInternet of Things (IoT) space. Technology company Harris Corporation (NYSE: HRS) is already a leading candidate to supply the FAA with real-time aircraft tracking data in partnership with Iridium Communications with the latter having a joint venture that has partnered with air traffic control authorities in Canada, Italy, Ireland and Denmark to provide air traffic surveillance (in cooperation with Harris).

Top 10 Medical Stocks To Invest In 2018: Quanta Services, Inc.(PWR)

Advisors’ Opinion:

  • [By Chad Tracy]

    TransCanada is not the only company that stands to profit from the possible Keystone XL approval. Refiners such as Valero and LyondellBasell Industries (NYSE: LYB), as well as construction companies Deere & Co. (NYSE: DE) and Quanta Services (NYSE: PWR) all stand to gain if Keystone XL gets the green light.

  • [By Ben Levisohn]

    Clinton 15 stock basket (DBUSCLNT): UnitedHealth Group (UNH), Humana (HUM), McKesson (MCK), Aecom (ACM), Quanta Services (PWR), ExxonMobil (XOM), Alcoa (AA), NextEra Energy (NEE), Cree (CREE), First Solar (FSLR), Facebook (FB), Netflix (NFLX), Prudential Financial (PRU), Citigroup (C), Union Pacific (UNP).

Top 10 Medical Stocks To Invest In 2018: Profire Energy, Inc.(PFIE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Profire Energy, Inc. (NASDAQ: PFIE) is estimated to post its quarterly earnings at $0.00 per share on revenue of $6.74 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 Medical Stocks To Invest In 2018: GSE Systems, Inc.(GVP)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggestedbuying small cap performance improvement stock GSE Systems (NYSEMKT: GVP):

    GSE Systems is another somewhat-preemptive position; we think the recent support at the 100-day moving average line (gray) and subsequent string of higher lows is telling. There’s a ceiling at $3.27 that needs to be cleared, but we fear waiting on that to happen because once it does, GVP shares could be catapulted to a price we don’t want to chase.

Top 10 Medical Stocks To Invest In 2018: Visa Inc.(V)

Advisors’ Opinion:

  • [By Paul Ausick]

    Of the three other stocks closest to Boeing’s yearly gain, Apple Inc. (NASDAQ: AAPL) added more than 2% to close the week up 51% for the year to date; Caterpillar Inc. (NYSE: CAT) rose by about 0.8% to a gain of more than 48%; and Visa Inc. (NYSE: V) tacked on 0.9% to bring its annual gain to 43.5%.

  • [By Elizabeth Balboa]

    Dozens of others spent more than $1 million, including Ally Financial Inc (NYSE: ALLY), Visa Inc (NYSE: V) and Navient Corp (NASDAQ: NAVI).

    Related Links:

  • [By Paul Ausick]

    The DJIA stock posting the largest daily percentage loss ahead of the close Monday was Visa Inc. (NYSE: V) which traded down 2.43% at $103.00. The stock’s 52-week range is $75.17 to $200.76. Volume was about 40% below the daily average of around 2.6 million. The company had no specific news.

Top 10 Medical Stocks To Invest In 2018: Sonoco Products Company(SON)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Deutsche Bank’s Debbie Jones and team contend that Sonoco’s (SON) sale of its plastic-container business to Australia’s Amcor is a sign that M&A is in the offing. They explain why:

    Sonoco announced (9/1) that it is selling its Rigid Plastics Blow Molding operations to Amcor (AMC.AU) for $280M. The transaction price represents a multiple of ~8.0x LTM EBITDA. The business had annual sales of ~$210M and consisted of six production sites in the US and one in Canada. Blow molding operations represented ~10% of Sonocos Consumer Packaging segment sales and EBITDA. The transaction is expected to close in Q4. We expect the proceeds to be used to for M&A focused in flexible packaging, thermoforming and temperature-assured packaging.

    We dont believe Sonoco considered its blow molding operations essential to its growth strategy. This standalone business is also more capital intensive compared to some of its other plastic packaging businesses and SON held a small position in the overall market. Ultimately, the company decided it wants to focus its capital in higher growth platforms. We do not expect the divestment to reduce resin buying scale for Sonoco’s remaining assets given different resin buying. Note that with the divestiture of blow molding and the Canton closures plant (divested in Feb. 2015), this makes the ~$100M reels business the last standalone business in the portfolio, but we do not expect this to be divested in the near-term unless cash is needed for much larger M&A.

    Shares of Sonoco have gained 1.3% to $52.49 at 2:12 p.m. today.


Top 10 Medical Stocks To Invest In 2018: Knowles Corporation(KN)

Advisors’ Opinion:

  • [By Jack Delaney]

    A deal with Facebook Inc. (Nasdaq: FB) brought the little-known Knowles Corp. (NYSE: KN) to investors’ attention today, boosting Knowles Corp. stock by 2.3% as of 12:30 p.m. today (Oct. 30, 2017).

Top 10 Medical Stocks To Invest In 2018: Noah Holdings Ltd.(NOAH)

Advisors’ Opinion:

  • [By Monica Gerson]

    Noah Holdings Limited (ADR) (NYSE: NOAH) is estimated to post financial results for its latest quarter.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 Medical Stocks To Invest In 2018: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.